Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L - PubMed
10 hours ago
- #survival analysis
- #multigene testing
- #recurrent NSCLC
- A retrospective multicenter study with 1500 advanced/recurrent NSCLC patients, including a post-operative recurrence subgroup of 229 patients, focused on biomarker testing rates and survival.
- Multigene testing was performed in 43.7% of post-operative recurrent cases, while 56.8% had single-gene testing; testing was more common in distant metastases (47%) than local recurrences (35%).
- Testing success did not differ significantly between resected preserved specimens and rebiopsied recurrent specimens, but multigene testing was less likely if recurrence occurred >3 years after surgery.
- Post-operative recurrent patients showed better overall survival compared to advanced-stage patients, both overall and in the driver-positive subgroup.
- The study highlights a low rate of multigene testing in post-operative recurrent NSCLC despite available surgical specimens, emphasizing the need for wider adoption to improve patient outcomes.